Prostate cancer patients may experience disturbed sleep as a result of their diagnosis or treatment. This study sought to evaluate disturbed sleep and excessive daytime sleepiness in newly diagnosed patients and those receiving androgen deprivation therapy (ADT). This study was conducted with 74 patients. Subjective data using the Pittsburgh Sleep Quality Index (PSQI) and Epworth Sleepiness Scale (ESS) and actigraphy data on ADT/ADT-naïve patients were collected. The prevalence of poor sleep quality, determined from PSQI and ESS scores, was 50% and 16.7% respectively. Those on ADT (n = 20) had poorer sleep quality as determined by significantly higher PSQI scores (70 vs. 40% scoring > 5) and were more likely to have poor sleep quality, sleep latency, and sleep efficiency than ADT-naïve patients (n = 40). Actigraphy data showed that ADT patients slept significantly longer (7.7 vs. 6.8 h), experienced a higher Fragmentation Index (48.3 vs. 37.4%), and had longer daytime nap duration (64.1 vs. 45.2 min) than ADT-naïve patients. The use of objective measures such as actigraphy in the clinical arena is recommended and may be used as a valuable tool for research into sleep assessment in prostate cancer patients.
Healthcare (Basel, Switzerland). 2022 Apr 30*** epublish ***
Shalini Mondal, Steve Edwards, Erik Wibowo, Hashim Ahmed, Richard J Wassersug, Jason Ellis, Maximus Isaac, Dagmara Dimitriou, Stephen Mangar
Sleep Education and Research Laboratory (SERL), UCL Institute of Education, London WC1H 0AA, UK., Clinical Trials Department, Imperial College Healthcare NHS Trust, London W6 8RF, UK., Department of Anatomy, University of Otago, Dunedin 9016, New Zealand., Department of Urology, Imperial College Healthcare NHS Trust, Charing Cross Hospital, London W6 8RF, UK., Department of Cellular and Physiological Sciences, Faculty of Medicine, University of British Columbia, Vancouver, BC V6T 1Z3, Canada., Northumbria Sleep Research Laboratory, Faculty of Health and Life Sciences, Northumbria University, 134/408 Northumberland Building, Newcastle upon Tyne NE1 8ST, UK., Department of Clinical Oncology, Imperial College Healthcare NHS Trust, Charing Cross Hospital, London W6 8RF, UK.